Lino-M Tablet 2.5 mg+850 mg is a fixed-dose combination of Linagliptin (2.5 mg), a Dipeptidyl Peptidase-4 (DPP-4) inhibitor, and Metformin Hydrochloride (850 mg), a biguanide. This combination is specifically designed to manage type 2 diabetes mellitus in adults who require dual therapy to achieve optimal glycemic control.

Linagliptin works by inhibiting DPP-4, an enzyme that degrades incretin hormones such as GLP-1 and GIP. This inhibition increases active incretin levels, enhancing glucose-dependent insulin secretion and reducing inappropriate glucagon release, thereby improving postprandial and fasting blood glucose levels.

Metformin Hydrochloride, on the other hand, reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity in peripheral tissues. The combination of these two agents addresses multiple mechanisms of hyperglycemia, providing comprehensive glucose control with a low risk of hypoglycemia and minimal weight gain.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Lino-M Tablet 2.5 mg+850 mg is indicated for:

• Adults with type 2 diabetes mellitus inadequately controlled with diet, exercise, and monotherapy

• Combination therapy when metformin alone does not achieve adequate glycemic control

• Patients needing complementary mechanisms of action to manage both fasting and postprandial hyperglycemia

This combination is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis.

Therapeutic Class

• Dipeptidyl Peptidase-4 (DPP-4) inhibitor

• Biguanide (Metformin)

Pharmacology

Linagliptin:

• Inhibits DPP-4, preventing degradation of incretin hormones

• Increases glucose-dependent insulin secretion from pancreatic beta cells

• Suppresses glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output

Metformin Hydrochloride:

• Decreases hepatic gluconeogenesis

• Improves peripheral glucose uptake and insulin sensitivity

• Delays intestinal glucose absorption

By combining Linagliptin and Metformin, Lino-M effectively addresses both insulin deficiency and insulin resistance, improving overall glycemic control.

Dosage & Administration

• Adults: Take one tablet twice daily with meals to reduce gastrointestinal side effects

• Can be used with other antidiabetic medications as per physician guidance

• Dosage adjustment may be required in patients with renal impairment or elderly patients

• Take the tablet with a glass of water; do not crush or chew

Contraindications

• Hypersensitivity to linagliptin, metformin, or any excipient

• Severe renal impairment, acute or chronic metabolic acidosis, including diabetic ketoacidosis

• Conditions predisposing to hypoxia or lactic acidosis

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Common side effects may include:

• Gastrointestinal disturbances: nausea, vomiting, diarrhea, abdominal discomfort

• Hypoglycemia, particularly when used with sulfonylureas or insulin

• Rare: pancreatitis, lactic acidosis, allergic reactions

Precautions & Warnings

• Monitor renal function before and during treatment

• Use caution in patients with liver disease, heart failure, or alcohol abuse

• Stop Metformin temporarily during radiologic studies involving iodinated contrast

• Educate patients about recognizing symptoms of lactic acidosis (fatigue, muscle pain, breathing difficulty)

Pregnancy & Lactation

• Pregnancy Category B: Use only if clearly necessary

• Metformin and linagliptin may pass into breast milk; use under medical supervision

Storage

Store in a dry place, below 30°C, away from light and moisture. Keep out of reach of children.

Lino-M Tablet 2.5 mg+850 mg provides a convenient, effective, and safe combination therapy for adults with type 2 diabetes mellitus, addressing multiple pathways of hyperglycemia and supporting long-term glycemic control.